Contact Us
Find A Doctor

The Collaborative Ocular Melanoma Study

New York Eye and Ear Infirmary of Mount Sinai (NYEE) participated as a clinical center for this 16-year nation-wide, multicenter study evaluating treatment options for intraocular (choroidal) melanoma. This study was the first National Institute of Health and The National Eye Institute sponsored study conducted at the NYEE.


  1. COMS Medium-sized Choroidal Melanoma Study: Eye and vision-sparing plaque radiation therapy was equivalent to enucleation (removal of the eye) for the prevention of metastatic choroidal melanoma at 5 and 10 years follow up.
  2. COMS Large-sized choroidal Melanoma Study: Pre-operative (20Gy) external beam radiation therapy did not improve survival after enucleation (removal of the eye).

Paul T Finger, MD was a Principal Investigator (PI) of this study performed at New York Eye and Ear Infirmary together with North Shore University Hospital.

Palladium-103 Ophthalmic Plaque Radiation Therapy

Since 1990, Dr. Finger first used a new isotope (radionuclide) for the treatment of intraocular tumors. Multiple dosimetry studies [even those performed by The American Association of Physicists in Medicine (AAPM)] have indicated that for most cases, Palladium-103 plaque therapy (Theragenics Corp. Buford, Georgia) offers a more favorable intraocular dose distribution than other types of radiation treatments for intraocular tumors.

Mitomycin C Eye Drops for Conjunctival Cancer

First discovered in 1993 by Drs. Finger and Milner at The New York Eye and Ear Infirmary, Mitomycin chemotherapy eye drops were used to treat malignant melanoma of the conjunctiva. Since then, Mitomycin eye drops are being used for conjunctival melanoma in centers around the world.

Anti-VEGF Therapy for Radiation Retinopathy and Optic Neuropathy

In 2007, Dr. Finger published the first reported experience using Avastin for radiation retinopathy and optic neuropathy. Published in the American Journal of Ophthalmology, the Archives of Ophthalmology and the International Journal of Radiation Oncology, Biology, Physics, Dr. Finger showed that anti-VEGF therapy decreased the hemorrhage, exudate and fluid causing radiation-related loss of vision after cancer therapy. This discovery means that patients who develop radiation-related retinal and optic nerve damage do not necessarily have to lose their vision.

Small incision iridectomy, iris and orbital tumor biopsy

The Finger Iridectomy Technique (FIT) and Finger’s orbital Aspiration Cutter Technique (FACT) allow for super-small typically self-sealing incisions that allow for biopsy, tumor diagnosis and rapid recovery. These techniques were first performed at The New York Eye and Ear Infirmary.

Contact Us

Dr. Paul Finger, Principal InvestigatorTel: (212) 832-8170

Address310 E. 14th Street
North Building, Retina Center/Ocular Tumor Service
New York, NY 10003

View all locations